Drug Combo Proves Powerful Against Lung Cancer Malone NY

A two-drug combination treatment in Malone proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Myrna Sanchez
(518) 483-0482
183 Park St Ste 5
Malone, NY
Sun Hua Liauw, MD
315-268-9314
23 4th St
Malone, NY
Ampey Luther III MD
(607) 798-5230
169 Riverside Dr
Binghamton, NY
Frank Alex H MD
(518) 926-6620
102 Park St
Glens Falls, NY
Upper Delaware Valley Cancer Center
(845) 294-1098
70 Hatfield Ln
Goshen, NY
Betty Danes
518-425-3379
PO Box 140
Chateaugay, NY
Betty Shannon Danes, MD
518-425-3379
PO Box 140
Chateaugay, NY
Eastern Long Island Hematology Oncology PC
(631) 204-9700
325 Meeting House Ln
Southampton, NY
Ifthkharuddin J J MD
(585) 275-5830
601 Elmwood Ave
Rochester, NY
Cancer Pain Specialists
(516) 663-2215
259 1st St
Mineola, NY
Data Provided by:
  

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Side Effect Of Chemotherapy Drugs Malone NY
Lung cancer remains the biggest cancer killer, projected to claim 163,510 lives this year. Paclitaxel will be used in the attempt to save the lives of many of these patients. However, one little-known effect of Paclitaxel is that in a subset of these patients there will be up to a fivefold increase in the production of Interleukin. Read on and learn more.
- Delayed Prostate Cancer Therapy Malone NY
- Exercise for Breast Cancer Survival Malone NY
- Genetic Clues for Skin Cancer Therapies Malone NY
- Hormone Therapy for Lung Cancer Malone NY
- Exercise for Prostate Cancer Malone NY
- Fungal Infection Treatments Malone NY
- Hormone Therapy for Breast Cancer Malone NY
- Risks for Childhood Cancer Survivors Malone NY